Morgan Stanley on Viking Therapeutics (VKTX): 'encouraged' by execution, patient demand

March 26, 2026 8:13 AM

Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $99.00 price target on Viking Therapeutics (NASDAQ: VKTX)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found